AgingResearch.NewsJoin free

Everolimus + letrozole

Intervention

1 paper2 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 1 lab in 1 country
  • Funders: National Cancer Institute and 1 more
  • Human trial1

Outcomes

2

Objective response rate

upin humans1

1 study

  1. Everolimus + letrozole increases objective response rate in humans (32% (11 of 35 patients)).

    Human trialrecurrent endometrial carcinomaoraleverolimus 10 mg daily + letrozole 2.5 mg dailycycles of 4 weeksfemalesn = 35

    Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology26 Jan 2015

Clinical benefit rate

upin humans1

1 study

  1. Everolimus + letrozole increases clinical benefit rate in humans (40% (14 of 35 patients)).

    Human trialrecurrent endometrial carcinomaoraleverolimus 10 mg daily + letrozole 2.5 mg dailycycles of 4 weeksfemalesn = 35

    Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology26 Jan 2015

Latest

Related